Cartesian Therapeutics (RNAC) Cash from Operations (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Cash from Operations of 22135000.0 for Q1 2026, up 4.21% year-over-year from 21240628.71 in Q1 2025, and down 24.97% quarter-over-quarter from 17712000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Cash from Operations (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Cash from Operations data on file, last reported at 22135000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 22135000.0, up 4.21% year-over-year; the trailing twelve-month figure through Mar 2026 was 72968000.0 (down 136.41% YoY), and the FY2025 annual result was 73941000.0, down 212.33% from the prior year.
- Cash from Operations declined to 22135000.0 in Q1 2026 per RNAC's latest filing, from 17712000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 13691000.0 in Q3 2024 and troughed at 23286000.0 in Q4 2023.
- A 5-year average of 11914235.29 and a median of 12271000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations slumped 311.69% in 2023, then jumped 248.57% in 2024.
- A 5-year view of Cash from Operations shows it stood at 11849000.0 in 2022, then plunged by 96.52% to 23286000.0 in 2023, then surged by 69.93% to 7002000.0 in 2024, then sank by 152.96% to 17712000.0 in 2025, then declined by 24.97% to 22135000.0 in 2026.
- Business Quant data shows RNAC's Cash from Operations at 22135000.0 in Q1 2026, 17712000.0 in Q4 2025, and 15600000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.14 Mn |
| Mar 31, 2026 | -22.14 Mn |
| Dec 31, 2025 | -17.71 Mn |
| Dec 31, 2025 | -17.71 Mn |
| Sep 30, 2025 | -15.60 Mn |
| Sep 30, 2025 | -15.60 Mn |
| Jun 30, 2025 | -17.52 Mn |
| Jun 30, 2025 | -17.52 Mn |
| Mar 31, 2025 | -23.11 Mn |
| Mar 31, 2025 | -23.11 Mn |
| Dec 31, 2024 | -7.00 Mn |
| Dec 31, 2024 | -7.00 Mn |
| Sep 30, 2024 | 13.69 Mn |
| Sep 30, 2024 | 13.69 Mn |
| Jun 30, 2024 | -14.45 Mn |
| Jun 30, 2024 | -14.45 Mn |
| Mar 31, 2024 | -15.92 Mn |
| Mar 31, 2024 | -15.92 Mn |
| Dec 31, 2023 | -23.29 Mn |
| Dec 31, 2023 | -23.29 Mn |